Miltefosine for New World Cutaneous Leishmaniasis
نویسندگان
چکیده
منابع مشابه
Miltefosine for new world cutaneous leishmaniasis.
The oral agent miltefosine has demonstrated a >95% cure rate in Indian visceral leishmaniasis. We performed a large, placebo-controlled study of miltefosine therapy (2.5 mg/kg per day orally for 28 days) against cutaneous leishmaniasis in Colombia and Guatemala. In regions in Colombia where Leishmania vianna panamensis is common, the per-protocol cure rates for miltefosine and placebo were 91% ...
متن کاملPharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.
The pharmacokinetics of miltefosine in leishmaniasis patients are, to a great extent, unknown. We examined and characterized the pharmacokinetics of miltefosine in a group of patients with Old World (Leishmania major) cutaneous leishmaniasis. Miltefosine plasma concentrations were determined in samples taken during and up to 5 months after the end of treatment from 31 Dutch military personnel w...
متن کاملResolution of Cutaneous Old World and New World Leishmaniasis after Oral Miltefosine Treatment
An Afghan migrant who had returned from a visit to the Middle East 2 years before was seen with a non-healing painless lesion on the forearm ( Figure 1A ). A skin biopsy showed intracellular Leishmania parasites in the subcutis ( Figure 1B and C ), and the polymerase chain reaction (PCR) was positive for Leishmania tropica . At the same time, a German traveler who had returned from a vacation t...
متن کاملDiffuse cutaneous leishmaniasis responds to miltefosine but then relapses.
BACKGROUND Diffuse cutaneous leishmaniasis (DCL), although rare, is profoundly incapacitating. At present there is no successful treatment for this progressive protozoan infection, which is associated with the absence of specific cell-mediated immunity (CMI) to Leishmania. This disease shares features with visceral leishmaniasis (VL), including specific CMI inactivity during active disease and ...
متن کاملPharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis
An open-label pharmacokinetics (PK) clinical trial was conducted to comparatively assess the PK and explore the pharmacodynamics (PD) of miltefosine in children and adults with cutaneous leishmaniasis (CL) in Colombia. Sixty patients, 30 children aged 2 to 12 years and 30 adults aged 18 to 60 years, were enrolled. Participants received miltefosine (Impavido) at a nominal dose of 2.5 mg/kg/day f...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Infectious Diseases
سال: 2004
ISSN: 1058-4838,1537-6591
DOI: 10.1086/383321